This open-label, single-dose, parallel-group study will investigate the pharmacokinetics and safety of RO4917838 in healthy and renal impaired subjects. Subjects will receive a single dose of RO4917838.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
12
Unnamed facility
Rennes, France
Unnamed facility
Moscow, Russia
Unnamed facility
Moscow, Russia
Pharmacokinetics: Area under concentration time curve of RO4917838
Time frame: Days 1-16
Safety: Incidence of adverse events
Time frame: 9 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.